Glucocorticoid-Induced Bone Loss Is Associated with Abnormal Intravertebral Areal Bone Mineral Density Distribution
Table 1
Descriptive measures for each group and pooled data, expressed as the mean (SD) for age, height, mass, and BMI and as the mean (95% CI) for FRAX data, -scores, and L3 area.
Descriptive measure
Group
Pooled
Primary osteoporosis
GIO
Control
(% female)
43 (95.3)
13 (30.8)
48 (83.3)
104 (81.7)
Age (years)
61.1 (5.0)
63.7 (7.8)
61.5 (5.6)
62.1 (6.1)
Height (cm)
163.1 (7.6)
169.1 (8.7)
166.8 (6.5)
166.3 (7.6)
Mass (kg)
61.8 (10.0)b,c
75.6 (16.1)a
71.9 (8.8)
69.8 (11.6)
BMI (kg/m2)
23.2 (3.0)b,c
26.2 (3.7)a
25.8 (2.8)
25.1 (3.2)
FRAX major osteoporotic (%)
4.5 (3.7 to 5.4)c
6.0 (3.3 to 8.7)c
2.6 (2.0 to 3.2)
4.4 (3.0 to 5.8)
FRAX hip (%)
1.1 (0.8 to 1.4)
2.1 (0.8 to 3.4)c
0.4 (0.1 to 0.7)
1.2 (0.6 to 1.8)
-score PA spine (L1–4)
−2.6 (−2.9 to −2.4)b,c
−1.6 (−2.4 to −0.9)a,c
0.0 (−0.2 to 0.3)
−1.4 (−1.8 to −1.0)
-score total hip
−2.0 (−2.2 to −1.8)b,c
−1.3 (−1.9 to −0.8)a,c
−0.2 (−0.4 to 0.1)
−1.8 (−1.5 to −0.8)
L3 area (ROI 1) (cm2)
8.8 (8.1 to 9.5)b
11.1 (10.1 to 12.0)a
9.9 (9.1 to 10.0)
9.9 (9.1 to 10.5)
Significant difference compared to the primary osteoporosis group (); bsignificant difference compared to the GIO group (); csignificant difference compared to control group ().
